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Global antibiotic consumption increased markedly between 
2000 and 2010, with Brazil, China, India, the Russian Federa-
tion and South Africa accounting for 76% of the increase.1 In 
response, the World Health Organization (WHO) developed 
a global action plan on antimicrobial resistance in 2015.2 The 
fourth objective of this plan is to optimize the use of antibiot-
ics. More recently, the classification of antibiotics in the WHO 
Model list of essential medicines has undergone substantial 
revision.3,4 The new AWaRe classification divides antibiotics 
into Access, Watch and Reserve antibiotic groups with the aim 
of encouraging their rational use and optimizing prescrib-
ing.3 Given this renewed focus on prudent antibiotic use, it is 
important that national prescribing guidelines are reviewed, 
any variations between countries are identified and the rea-
sons for those variations are understood. Antimicrobials are 
the most commonly prescribed class of drugs for children.5–9 
Historically, however, paediatric dosing regimens have often 
been derived from pharmacokinetic data in adults, with the 
assumption that the relationship between drug exposure and 
total body weight is linear.10,11 This approach, although clini-
cally widespread, is not supported by solid empirical evidence 
and may result in neonates and children being exposed to 
inappropriate systemic drug levels.12,13 The potential impact of 
inappropriate drug use in children on selection for antimicro-
bial resistance and the development of toxicity is unknown.
Clinicians’ prescribing practices are often informed by 
formularies, which recommend antibiotic doses that bal-
ance efficacy, toxicity and drivers of antimicrobial resistance. 
However, recommendations are frequently based on historical 
practice rather than evidence.14 For children, in particular, few 
data on efficacy, safety and pharmacokinetics are available.15–17 
Traditionally, there has been a preference for weight-based 
dosing strategies in the United States of America, whereas 
the United Kingdom of Great Britain and Northern Ireland 
has preferred age-banded dosing and WHO has preferred 
weight-banded dosing. This lack of standardization has 
resulted in widely varying recommendations and heteroge-
neous guidance, which have created ambiguities, especially 
for inexperienced clinicians.18,19 While there has tended to 
be some agreement on adult dosing guidance, for example 
between the National Institute for Health and Care Excellence 
in the United Kingdom and the Infectious Diseases Society 
of America in the United States, this has not been the case 
for children.20,21 Our view is that the international variation 
in guidance on paediatric dosing is most likely not based on 
different rates of antimicrobial resistance or clinical disease 
patterns, but instead reflects historical and cultural practices 
and the absence of a solid evidence base.
Although previous efforts have been made to compare 
local paediatric antibiotic guidelines, to the best of our 
knowledge there has been no detailed comparison of guid-
ance from leading paediatric antibiotic formularies globally.22 
Consequently, the aim of our study was to compare antibiotic 
guidance in the paediatric antibiotic formularies of both high-
income countries and emerging economies for 32 commonly 
prescribed antibiotics on the 2017 WHO Model list of essential 
medicines for children.23
Methods
We identified antibiotic guidelines that were either widely used 
internationally or originated in countries in which antibiotic 
use has increased markedly in recent years (i.e. Brazil, China, 
India, the Russian Federation and South Africa).1 In particular, 
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we looked for guidance in these coun-
tries that had been endorsed by national 
and international bodies by contacting 
national coordinators of the Global 
Antibiotic Resistance, Prescribing and 
Efficacy among Neonates and Children 
(GARPEC) network.24 Our aim was not 
to review all existing antibiotic guidance 
from every country comprehensively or 
to identify all patient management path-
ways. Instead, we selected guidelines 
that included specific paediatric dosing 
formularies or summaries, namely:
i) Manual of childhood infections: the 
blue book, 4th edition, 2016, which 
is endorsed by the Royal College of 
Paediatrics and Child Health in the 
United Kingdom and the European 
Society of Paediatric Infectious 
Diseases and is a leading handbook 
used in Europe;11
ii) BNF (British national formulary) 
for children, 2017, which is a com-
monly used paediatric reference for 
prescribing in the United King-
dom;25
iii) Red book®: 2018–2021 report of the 
committee on infectious diseases, 
31st edition, which is endorsed by 
the American Academy of Pedi-
atrics Committee on Infectious 
Diseases;26
iv) Pocket book of hospital care for 
children, second edition, 2013, from 
WHO, which is part of a series of 
documents and tools that support 
the integrated management of 
childhood illness;27 and
v) Indian National treatment guidelines 
for antimicrobial use in infectious 
diseases, 2016, which were devel-
oped by the Indian National Centre 
for Disease Control.28
Although we consulted national experts, 
we were unable to find paediatric anti-
biotic guidelines from Brazil, China, the 
Russian Federation or South Africa that 
were clearly endorsed nationally.
From each publication, we ob-
tained the recommended dosage of 
all antibiotics listed in section: 6.2 
(i.e. antibacterials) of the 2017 WHO 
Model list of essential medicines for 
children, with the exception of: (i) ben-
zathine benzylpenicillin; (ii) procaine 
benzylpenicillin; (iii) cefixime; (iv) ti-
gecycline; (v) fosfomycin; (vi) dapto-
mycin; (vii) polymyxins (e.g. colistin); 
(viii) fourth-generation cephalosporins, 
with or without a β-lactamase inhibitor 
(e.g. cefepime); and (ix) fifth-generation 
cephalosporins, with or without a 
β-lactamase inhibitor (e.g. ceftaroline). 
We included levofloxacin in our analy-
sis even though it was not listed in the 
2017 model list. We grouped the final 
selection of 32 antibiotics into the three 
AWaRe categories and compared dosing 
recommendations made by the different 
guidelines.
The BNF for children, in general, 
arranges guidance by route of adminis-
tration and then by age band. The Blue 
book provides guidance by drug, giving 
the dose in milligrams per kilogram 
and the dosing frequency per day. The 
Red book® presents separate tables for 
neonates and children, with neonatal 
doses stratified by gestational age and 
then by postnatal age (where applicable): 
paediatric recommendations are given 
as a total daily dose per kilogram with a 
frequency of administration. The Pocket 
book of hospital care for children presents 
separate summary tables for neonates 
and children; guidance on neonatal dos-
ing is given by route of administration 
and stratified by age into the first week 
of life and a postnatal age of 2 to 4 weeks. 
The Indian National Centre for Disease 
Control guidelines present two dosing 
summary tables: (i) a dosing guide for 
commonly used antimicrobial agents; 
and (ii) drug doses in the paediatric 
age group. We primarily used informa-
tion from the first table, as the second 
table was less complete. However, we 
consulted the second table and the text 
to resolve inconsistencies. The Indian 
guidance did not present a separate table 
for neonates. 
Where possible, we present doses 
in mg/kg per day or mg/day along with 
dosing frequency to enable guidelines 
to be compared. When dosing guid-
ance was given for specific syndromes 
or suspected causative organisms, we 
included those for priority syndromes 
(i.e. pneumonia, sepsis, acute otitis 
media, pharyngitis and urinary tract 
infection) and for severe infection, 
especially meningitis. We excluded 
prophylactic doses, loading doses and 
doses for nonpriority syndromes and for 
low- or very-low-birthweight infants. In 
all cases where the guidance provide in 
summary tables was unclear, we con-
sulted the primary text.
Results
For all 32 antibiotics studied, there were 
differences in recommended dosages 
across the five guidelines (Table 1 ; avail-
able at: http://www.who.int/bulletin/
volumes/98/6/19-234310). Of all the 
guidelines, the Pocket book gave dos-
ing guidance for the fewest antibiotics 
reviewed (i.e. 12 of 32); it did not give 
recommendations for some commonly 
used Access (e.g. amoxicillin with clavu-
lanic acid, phenoxymethylpenicillin and 
amikacin) and Watch (e.g. meropenem, 
piperacillin–tazobactam and vanco-
mycin) antibiotics. In fact, it included 
guidance on only one antibiotic in the 
Watch group (i.e. erythromycin) and 
none in the Reserve group. 
The number of dosing bands var-
ied across guidelines, with the BNF for 
children tending to have the most and 
the Pocket book and the Indian National 
Centre for Disease Control guidelines 
having the fewest. The rationale for 
choosing different weight or age bands 
was not apparent, pharmacokinetic evi-
dence was neither cited nor, if available, 
explained.29
There was a considerable variation 
in recommended doses for each antibi-
otic. For example, Fig. 1 illustrates that 
the recommended dose of oral amoxicil-
lin for a 5-year-old child weighing 18 kg 
with suspected nonsevere pneumonia 
varied from 360 mg per day (using the 
lower end of the Indian National Centre 
for Disease Control guidance of 20 mg/
kg per day) to 1620 mg per day (using 
the upper end of the Blue book guidance 
of 90 mg/kg per day). Moreover, the 
five guidelines all proposed different 
age ranges for dosing and the suggested 
dosing interval was 6, 8 or 12 hours.
Discussion
We found marked differences between 
the guidelines reviewed on paediatric 
dosing recommendations for 32 com-
monly prescribed antibiotics. There were 
differences in the age basis for dosing 
(e.g. the use of postnatal age alone or in 
combination with weight or gestational 
age), the frequency of administration 
and the total daily dose. Although some 
of this heterogeneity may reflect differ-
ences between settings in epidemiology, 
risk factors, causative organisms (e.g. 
due to different vaccination policies) 
or patterns of antibiotic resistance and 
may therefore be appropriate, other 
variations (e.g. the use of different age 
or weight dosing bands) can create 
confusion. In many instances, it is dif-
ficult to discern the rationale behind 
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the dosing recommendations, whether 
they are derived from the accompany-
ing summary of product characteris-
tics, academic publications or expert 
consensus. Several national paediatric 
formularies, such as the Dutch, Italian 
and Spanish formularies, have been 
developed, but have been criticized for 
not presenting the underlying evidence 
or for referring to outdated paediatric 
dosing handbooks.30,31 However, the 
Dutch formulary has clearly tried to 
address this issue.32
Variations between guidelines may 
partly be due to a lack of robust evidence 
on the best treatment. In addition, defin-
ing optimal drug dosing is more com-
plex for children than adults: antibiotic 
doses must be adapted to maturational 
changes in pharmacokinetics and con-
sider changes in pharmacodynamics, yet 
still be simple and pragmatic. However, 
few studies on antibiotic pharmacoki-
netics or effectiveness have been per-
formed in children.17,33 Further, most 
of the guidelines we considered did not 
explicitly reference the evidence under-
lying their recommendations. The Blue 
book alone indicated the strength of the 
recommendations for each individual 
dose but did not present the supporting 
evidence. Moreover, the pharmacoki-
netic data underpinning many older 
off-patent antibiotics are very limited 
and were based on studies that were not 
conducted in accordance with recent 
standards.34
A few strategic trials in children 
have examined high- and low-dose 
strategies and have reported efficacy and 
toxicity outcomes. However, these stud-
ies have used widely varying inclusion 
and exclusion criteria and end-points, 
which makes data synthesis between 
trials difficult. In addition, the absence 
of formal regulatory guidance on the 
design and conduct of antibiotic clinical 
trials in neonates and children has also 
hampered studies of clinical effective-
ness. Our ability to compare therapies 
and treatment strategies would be im-
proved by international collaboration 
to agree case definitions and outcome 
measures, similar to the collaboration 
that was effective in developing harmo-
nized guidance for paediatric prescrib-
ing of antiretroviral drugs.35
Dosing bands
The different age and weight dosing 
bands in leading global guidelines 
have been influenced by both practical 
considerations and historical usage. 
Although the most accurate method is 
to select the dose by weighing the child, 
this is not always possible. Simulations 
of orally administered amoxicillin in 
children show that the use of weight 
bands, rather than the exact weight, 
can often result in the administration 
of drug doses outside the therapeutic 
range.14 Perhaps the simplest method of 
dose selection is to use age as a proxy for 
weight, though in practice this is often 
the least accurate method. Nevertheless, 
it can be useful when the child’s recent 
weight is unknown, especially for drugs 
with a high therapeutic index (i.e. rela-
tively safe drugs). Age bands need to be 
defined in a way that considers: periods 
of rapid weight change (e.g. during the 
first 6 months of life and around 8 to 
9 years of age); the normal distribution 
of weight around the 50th percentile for 
specific ages; and local weight-for-age 
norms.14 Although there are theoreti-
cal concerns that underdosing can in-
crease the risk of treatment failure (the 
therapeutic level may not be reached) 
or promote resistance selection, these 
risks can be proved only in large clinical 
trials. On the other hand, children who 
receive too high a dose may experience 
adverse events and discontinue treat-
ment. Antibiotic-associated diarrhoea is 
the most common side-effect of penicil-
lin in children, with oral penicillin, the 
rate is increased in younger children 
and there appears to be an association 
with higher doses.36 However, it remains 
unclear whether the child’s age or the 
drug’s formulation or dose is the main 
driver of severe diarrhoea.36
Gaps in guidance
We identified several important omis-
sions in global guidelines. First, we were 
unable to identify nationally endorsed, 
comprehensive treatment and dos-
ing guidelines from Brazil, China, the 
Russian Federation or South Africa, 
although some individual institutions 
had their own local guidance. A unified 
approach within and, where appropriate, 
between countries would increase treat-
ment standardization and make it easier 
to integrate the evidence. It is likely that 
many other countries, particularly low- 
and middle-income countries, also lack 
country-specific guidance and may have 
adopted recommendations developed 
elsewhere. In fact, published evidence 
often focuses on high-income settings, 
with little representation of low- or 
middle-income countries.4 However, 
guidelines developed in one country 
may not be appropriate for countries 
where the epidemiology and burden of 
infectious diseases is different. Second, 
further research is needed into clinical 
syndromes in which the antibiotic dose 
must be altered to take account of vary-
Fig. 1. Oral amoxicillin doses recommended by five guidelines for an 18-kg, 5-year-old 
child with suspected nonsevere pneumonia, 2018
Pocket booka
1440 mg orally, given in two 
divided doses
Indian National Centre for 
Disease Controlb
360–900 mg orally, given in three 
or four divided doses
Red book®d
720–810 mg orally, given in three 
divided doses
Five-year-old child, weighing 
18 kg, with suspected 
nonsevere pneumonia
British national formulary 
for childrenc
1500 mg orally, given in three 
divided doses
Blue booke
810–1620 mg orally, given in three 
divided doses
a Pocket book of hospital care for children, second edition.27
b National treatment guidelines for antimicrobial use in infectious diseases.28
c BNF (British national formulary) for children.25
d Red book®: 2018–2021 report of the committee on infectious diseases, 31st edition.26
e Manual of childhood infections: the blue book, 4th edition.11
409Bull World Health Organ 2020;98:406–412F| doi: http://dx.doi.org/10.2471/BLT.19.234310
Research
Paediatric dosing guidelines for antibioticsShrey Mathur et al.
ing levels of drug resistance. Finally, it 
should be recognized that European, 
United States’ and WHO guidelines were 
all developed at a similar time and were 
all based on the same rapidly evolving 
evidence.
Conclusions
The wide variation in paediatric antibi-
otic dosing recommendations we found 
between leading formularies could be 
rectified by: (i) carrying out a systematic 
review of the pharmacokinetic and clini-
cal evidence underpinning current glob-
al guidance on the most commonly used 
antibiotics in children; (ii) producing an 
evidence-based, transparent, consensus, 
guidance document on the optimal 
dosing of Access antibiotics based on 
current knowledge; and (iii) identifying 
antibiotics that should be a priority for 
future research because more evidence 
is needed to optimize paediatric dosing, 
the nature of the evidence needed should 
be clear. Interested global parties could 
be brought together under the auspices 
of WHO’s antibiotic working group on 
the Model List of Essential Medicines 
for Children to develop an evidence-
based consensus and identify research 
priorities.3 ■
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结果 这项研究分析考量了五大抗生素指南 ：(i) 《儿童
感染手册 ：蓝皮书》（Manual of childhood infections: the 
blue book）；(ii) 《英国国家儿童处方集》（BNF (British 
national formulary) for children）；(iii)《红皮书 ：2018–
2021 传 染 病 委 员 会 报 告 》（Red book®: 2018–2021 
report of the committee on infectious diseases）；(iv) 世界
卫生组织发布的《儿童医院护理口袋书》（Pocket book 
of hospital care for children）以及 (v)《印度传染病使
用抗菌药物国民治疗指南》（Indian national treatment 












لافطلأل ةيويلحا تاداضلما تاعرلج ةيهيجوت ئدابم ةسخم ينب ةنراقم
 لافطلأا ةيودأ تابيكرت في تاعرلجا تاداشرإ ينب ةنراقم ضرغلا
 تاداضلما  نم  32  ـل  طسوتلماو  عفترلما  لخدلا  تاذ  نادلبلا  في
 ةحصلا ةمظنلم ةيجذومنلا ةمئاقلا في عئاش لكشب ةفوصولما ةيويلحا
.لافطلأل ةيساسلأا ةيودلأل 2017 ماعل (WHO) ةيلماعلا
 ةيويلحا  تاداضملل  ةيهيجوتلا  ئدابلما  ديدحتب  انمق  ةقيرطلا
 وأ ،ليود لكشب عساو قاطن لىع اهمادختسا امإ مت يتلاو ،لافطلأل
 لكشب ةيويلحا تاداضلما مادختسا اهيف داز يتلا نادلبلا في تأشن
 داتحلااو دنلهاو ينصلاو ليزابرلا يأ) ةيرخلأا تاونسلا في ظوحلم
.(ايقيرفإ بونجو سيورلا
 ةيساسأ  ةيهيجوت  ئدابم  ةسخم  لىع  ةساردلا  ليلتح  زكترا  جئاتنلا
 ؛قرزلأا  باتكلا  :ةلوفطلا  ضارمأ  بيتك  :ةيويلحا  تاداضملل
 ؛لافطلأل  (BNF)  ةيناطيبرلا  ةينطولا  ةيودلأا  تابيكرت  (ب)و
 ضارملأا ةنلج نم ريرقت :)®Red Book( رحملأا باتكلا (ج)و
 ةحصلا  ةمظنم  باتك  (د)و ؛2021  لىإ  2018  نم ةترفلل  ةيدعلما
 (ـه)و  ؛تايفشتسلما  في  لافطلأا  ةياعر  نع  بيجلل  ةيلماعلا
 تاداضم مادختسلا يدنلها  ينطولا  جلاعلا  في ةيهيجوتلا  ئدابلما
 ظوحلم  سناتج  مدع  كانه  ناك  .ةيدعلما  ضارملأا  في  تابوركيلما
 تاعرلجا  تاقاطنو  ،ةيمويلا  ةعرلجا  يأ)  ابه  صىولما  تاعرلجا  في
 رثكلأا  ةيويلحا  تاداضملل  ةبسنلاب  (ةعرلجا  راركتو  ،ةيرمعلا
 يرغ  تاعرلجا  تايصوت  ءارو  يقطنلما  ببسلا  ناك  .ًامادختسا
.ماع لكشب حضاو
 ،ةيئاودلا اكيمانيدلاو ،ءاودلا تايكرح ينستح بيج جاتنتسلاا
 ،لافطلأل ةيويلحا تاداضلما تاعرج معدت يتلا ةيريسرلا ةلدلأاو
 ةصالخا  تاعرلجا  حئاشر  لىعو  ةيلكلا  تاعرلجا  لىع  ةصاخو
 رابتعلاا  في  ةيلبقتسلما  ثاحبلأا  عضت  نأ  بيج  .نزولا  وأ  رمعلاب
 طمانأ نع أشنت ددحلما يهيجوتلا أدبلما في تافلاتخلاا تناك اذإ ام
 تاداضلما ةمواقم نم ةفلتمخ تايوتسم وأ ،ضارملأل ةفلتمخ ةيريسر
 نكمي .ةييخرات تلايضفت درمج تسيلو ،ةيودلأا رفاوت وأ ،ةيويلحا
 تاداضلما  لمع  ةعوممج  عم  نواعتت  نأ  ةينعلما  ةيلماعلا  فارطلأل
 (WHO)  ةيلماعلا  ةحصلا  ةمظنلم  ةيجذومنلا  ةمئاقلا  في  ةيويلحا
 لىع  مئاق  عاجمإ  لىإ  لوصولا  فدبه  ،لافطلأل  ةيساسلأا  ةيودلأل
 .ثحبلا تايولوأ ديدتحو ةلدلأا
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Résumé
Comparaison entre cinq recommandations de dosage des antibiotiques à usage pédiatrique
Objectif Comparer la posologie des listes de médicaments pédiatriques 
dans les pays à haut et moyen revenu pour 32 antibiotiques 
fréquemment prescrits figurant sur l'édition 2017 de la Liste modèle des 
médicaments essentiels destinés à l'enfant de l'Organisation mondiale 
de la Santé (OMS).
Méthodes Nous avons identifié plusieurs directives thérapeutiques 
concernant les antibiotiques à usage pédiatrique, soit largement 
appliquées à l'échelle internationale, soit émanant de pays où le recours 
aux antibiotiques a considérablement augmenté ces dernières années 
(Brésil, Chine, Inde, Fédération de Russie et Afrique du Sud).
Résultats L'analyse réalisée dans le cadre de l'étude a porté sur cinq 
recommandations majeures pour le dosage des antibiotiques: (i) le 
Manual of childhood infections: the blue book; (ii) le BNF (British national 
formulary) for children; (iii) le Red book®: 2018–2021 report of the committee 
on infectious diseases; (iv) le Livre de poche pour soins hospitaliers 
pédiatriques de l'OMS; et enfin, (v) les Indian national treatment guidelines 
for antimicrobial use in infectious diseases. La posologie recommandée 
varie beaucoup d'un ouvrage à l'autre (dose journalière, dosage en 
fonction de la tranche d'âge et fréquence d'administration) pour la 
plupart des antibiotiques les plus répandus. La logique derrière ces 
recommandations posologiques n'était généralement pas claire.
Conclusion Les données pharmacocinétiques, pharmacodynamiques 
et cliniques justifiant la posologie des antibiotiques destinés aux enfants 
doivent être améliorées, en particulier pour les doses totales ainsi que le 
dosage lié à l'âge ou au poids corporel. Les recherches complémentaires 
devraient déterminer si les variations de recommandations découlent 
de différents schémas de pathologies cliniques, de niveaux de résistance 
aux antibiotiques distincts ou de disponibilité des médicaments, ou s'il 
s'agit plutôt de préférences historiques. Les parties concernées à l'échelle 
mondiale pourraient collaborer avec le groupe de travail à l'origine de 
la Liste modèle des médicaments essentiels destinés à l'enfant de l'OMS, 
afin de parvenir à un consensus fondé sur des données concrètes et 
d'identifier les priorités de recherche.
Резюме
Сравнение пяти руководящих принципов по определению дозировки антибиотиков для детей
Цель Сравнить руководящие принципы по определению 
дозировки 32 наиболее часто назначаемых антибиотиков для 
детей в странах с высоким и средним уровнем дохода с учетом 
принятого Всемирной организацией здравоохранения (ВОЗ) 
в 2017 г. Примерного перечня жизненно важных лекарственных 
препаратов для детей.
Методы Авторы рассмотрели руководящие принципы по 
применению антибиотиков в педиатрии, которые либо широко 
использовались в международной практике, либо были 
разработаны в странах, где в последние годы применение 
антибиотиков сильно возросло (например, Бразилия, Индия, 
Китай, Российская Федерация и Южная Африка).
Результаты В рамках исследования анализировались пять 
ведущих руководящих принципов по применению антибиотиков: 
(i) «Руководство по инфекционным заболеваниям у детей: 
официальный сборник документов» (Manual of childhood infections: 
the blue book); (ii) «Британский национальный педиатрический 
формуляр» (BNF (British national formulary) for children); (iii) «Красная 
книга: отчет комитета по инфекционным заболеваниям за 
2018–2021 годы» (Red book®: 2018–2021 report of the committee on 
infectious diseases); (iv) изданный ВОЗ «Карманный справочник 
по больничному уходу за детьми» (Pocket book of hospital care 
for children); (v) «Индийские национальные рекомендации по 
применению антимикробных препаратов при инфекционных 
заболеваниях» (Indian national treatment guidelines for antimicrobial 
use in infectious diseases). Рекомендуемые дозировки (суточные 
дозы, диапазоны доз по возрасту и частота приема) для 
большинства наиболее распространенных антибиотиков сильно 
различались. Обоснования для рекомендаций по дозировке, как 
правило, были нечеткими.
В ы в о д  Н е о б х о д и м о  с о в е р ш е н с т в о в а т ь  с и с т е м у 
фармакокинетических, фармакодинамических и клинических 
данных, обосновывающих дозировку антибиотиков для 
детей, в частности в отношении общей дозы, возрастных 
диапазонов или диапазонов из расчета на массу тела. В будущих 
исследованиях следует выяснить, являются ли обнаруженные 
расхождения в рекомендациях скорее следствием различных 
картин клинических проявлений болезней, неоднородной 
резистентности к антибиотикам или доступности препаратов, 
чем желанием следовать исторически сложившимся традициям. 
Заинтересованные представители мирового сообщества могут 
сотрудничать с рабочей группой по вопросам применения 
антибиотиков на основе издаваемого ВОЗ Примерного перечня 
жизненно важных лекарственных препаратов для детей с целью 
разработки единого мнения, основанного на доказательном 
подходе, и определения приоритетов исследований.
Resumen
Una comparación de cinco recomendaciones sobre la dosificación pediátrica de los antibióticos
Objetivo Comparar las recomendaciones de dosificación en los 
medicamentos pediátricos de los países de ingresos altos y medios 
de 32 antibióticos que se recetan con frecuencia en la Lista modelo de 
medicamentos pediátricos esenciales de 2017 de la Organización Mundial 
de la Salud (OMS).
Métodos Se identificaron las recomendaciones sobre los antibióticos 
pediátricos que se utilizaban mucho a nivel internacional o que 
procedían de países en los que el uso de antibióticos había aumentado 
notablemente en los últimos años (es decir, Brasil, China, la Federación 
de Rusia, India y Sudáfrica).
Resultados El análisis del estudio consideró cinco recomendaciones 
principales sobre los antibióticos: (i) el Manual de infecciones infantiles: el 
libro azul (Manual of childhood infections: the blue book); (ii) el Formulario 
nacional británico (British national formulary, BNF) para niños; (iii) el Red 
book®: informe del comité de enfermedades infecciosas de 2018-2021 (Red 
book®: 2018-2021 report of the committee on infectious diseases); (iv) la Guía 
de bolsillo sobre la atención hospitalaria de los niños de la OMS (WHO's 
Pocket book of hospital care for children); y (v) las Directrices nacionales de 
tratamiento para el uso de antimicrobianos en las enfermedades infecciosas 
de la India (Indian national treatment guidelines for antimicrobial use in 
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infectious diseases). Se observó una marcada heterogeneidad en la 
dosificación recomendada (es decir, dosis diaria, grupos de dosificación 
por edad y frecuencia de la dosis) de los antibióticos más utilizados. En 
general, los motivos de las recomendaciones sobre la dosificación no 
estaban claros.
Conclusión Se deben mejorar las evidencias farmacocinéticas, 
farmacodinámicas y clínicas que respaldan la dosificación de los 
antibióticos pediátricos, en especial sobre las dosis totales y sobre los 
grupos de dosificación por edad o peso. Las investigaciones futuras 
deben considerar si las variaciones en las recomendaciones identificadas 
se derivan de diferentes patrones clínicos de la enfermedad, de niveles 
variables de resistencia a los antibióticos o de la disponibilidad de 
los medicamentos, más que de las preferencias históricas. Las partes 
interesadas a nivel mundial podrían colaborar con el grupo de trabajo 
sobre antibióticos de la Lista modelo de medicamentos esenciales de 
la OMS para desarrollar un consenso basado en las evidencias y para 
identificar las prioridades de investigación.
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Table 1. Dosing recommendations in five widely used, guidelines for 32 commonly prescribed, paediatric antibiotic formulations, 2018
Antibiotic Guidelines, dosing recommendations, by age group, administration route, dosage, frequency
BNF for childrena Blue bookb Red book® c Pocket bookd Indian National Centre for 
Disease Controle
Amikacin Neonate:
• intravenous, 15 mg/kg per day, q24h; 
1 month – 11 years:
• intravenous, 15 mg/kg per day, q12h; 
12–17 years:
• intravenous, 15 mg/kg per day, q12h
Neonate:
• intravenous, 15 mg/kg per day, 
q36h (PMA: ≤ 28 weeks); 
• intravenous, 15 mg/kg per day, 
q24h (PMA: > 28 weeks); 
1 month – 18 years:
• intravenous, 15 mg/kg per day, 
q24h
≤ 7 days (GA: ≥ 35 weeks):
• intramuscular/intravenous,15 mg/kg 
per day, q24h; 
 > 7 days (GA: ≥ 35 weeks):
• intramuscular/intravenous, 18 mg/kg 
per day, q24h; 
≤ 14 days:
• intramuscular/intravenous, 15 mg/kg 
per day, q48h (GA: <  30 weeks); 
• intramuscular/intravenous, 15 mg/kg 
per day, q36h (GA: 30–34 weeks); 
> 14–28 days:
• intramuscular/intravenous, 15 mg/kg 
per day, q24h (GA: < 30 weeks); 
• intramuscular/intravenous, 15 mg/kg 
per day, q24h (GA: 30–34 weeks); 
> 28 days:
• intramuscular/intravenous, 15–
22.5 mg/kg per day, q8h–q12h or q24h
No information • intravenous, 15–22.5 mg/kg per 
day, q8h–q12h
Amoxicillin < 7 days:
• intravenous, 60 mg/kg per day, q12h; 
7 days – 1 month:
• oral/intravenous, 90 mg/kg per day, 
q8h; 
 > 1–11 months:
• oral, 375 mg/day, q8h; 
1–4 years:
• oral, 750 mg/day, q8h; 
Child:
• intravenous, 60–90 mg/kg per day, 
q8h; 
5–11 years:
• oral, 1500 mg/day, q8h; 
12–17 years:
• oral, 1500 mg/day, q8h
< 7 days:
• oral/intravenous, 60–120 mg/kg 
per day, q12h; 
7–28 days:
• oral/intravenous, 90–180 mg/kg 
per day, q8h; 
1 month – 18 years:
• oral, 45–90 mg/kg per day, q8h; 
• intravenous, 90–180 mg/kg per 
day, q8h
> 28 days – 11 years:
• oral, 40–45 mg/kg per day, q8h 
(standard dose); 
• oral, 80–90 mg/kg per day, q12h 
(high dose); 
• oral, 90 mg/kg per day, q12h (acute 
otitis media); 
• oral, 50 mg/kg per day, q24h 
(streptococcal pharyngitis); 
≥ 12 years:
• oral, 775 mg/day (extended-release 
formulation), q24h
• oral, 50 mg/kg per day, 
q12h; 
• oral, 80 mg/kg per day, 
q12h (pneumonia)





• oral, 0.75 mL/kg per day (125/31 
suspension), q8h; 
• intravenous, 60 mg/kg per day, q12h; 
1–2 months:
• intravenous, 60 mg/kg per day, q12h; 
1–11 months:
• oral, 0.75 mL/kg per day (125/31 
suspension), q8h; 
3 months – 17 years:
• intravenous, 90 mg/kg per day, q8h; 
1–5 years:
• oral, 0.75 mL/kg per day (125/31 
suspension), q8h; 
6–11 years:
• oral, 0.45 mL/kg per day (250/62 
suspension), q8h; 
12–17 years:
• oral, 750 mL/day (250/62 suspension), 
q8h
< 28 days:
• oral, 0.75 mL/kg per day (125/31 
suspension), q8h; 
• intravenous, 60 mg/kg per day, 
q12h; 
1–3 months:
• intravenous, 90 mg/kg per day, 
q8h; 
1 month – 6 years:
• oral, 0.75–1.5 mL/kg per day 
(125/31 suspension), q8h; 
2 months – 18 years:
• oral, 0.3–0.4 mL/kg per day (400/57 
suspension), q12h; 
3 months – 18 years:
• intravenous, 90–120 mg/kg per 
day, q6h–q8h; 
6–12 years:
• oral, 0.45–0.9 mL/kg per day 
(250/62 suspension), q8h; 
12–18 years:
• oral, 250/125-mg tablet, q8h; 
• oral, 500/125-mg tablet, q8h 
(severe infection)
> 28 days:
• oral, 90 mg/kg per day (14 : 1 
formulation), q12h; 
• oral, 25–45 mg/kg per day (7 : 1 
formulation), q12h; 
• oral, 20–40 mg/kg per day (4 : 1 
formulation), q8h
No information • oral/intravenous, 40 mg/kg per 
day, q12h
Ampicillin < 7 days:
• intravenous, 60 mg/kg per day, q12h; 
7–20 days:
• oral/intravenous, 90 mg/kg per day, 
q8h; 
21–28 days:
• oral/intravenous, 120 mg/kg per day, 
q6h; 
1 month – 18 years:
• intravenous, 100 mg/kg per day, q6h; 
1–11 months:
• oral, 500 mg/day, q6h; 
1–4 years:
• oral, 1000 mg/day, q6h; 
5–11 years:
• oral, 2000 mg/day, q6h; 
12–17 years:
• oral, 2000 mg/day, q6h
≤ 7 days:
• oral/intravenous, 60–120 mg/kg 
per day, q12h; 
7–21 days:
• oral/intravenous, 90–180 mg/kg 
per day, q8h; 
21 days – 1 month:
• oral/intravenous, 120–240 mg/kg 
per day, q6h; 
1 month – 18 years:
• oral, 60–120 mg/kg per day, q6h; 
• intravenous, 100 mg/kg per day, 
q6h; 
• intravenous, 200 mg/kg per day, 
q6h (severe infection); 
• intravenous, 600 mg/kg per day, 
q4h (meningitis)
≤ 7 days:
• intramuscular/intravenous, 50 mg/kg 
per day, q12h (GA: ≤ 34 weeks); 
• intramuscular/intravenous, 50 mg/kg 
per day, q8h (GA: > 34 weeks); 
> 7–28 days (GA: ≤ 34 weeks):
• intramuscular/intravenous, 75 mg/kg 
per day, q12h; 
> 28 days:
• oral, 50–100 mg/kg per day, q6h; 
• intramuscular/intravenous, 50–
200 mg/kg per day, q6h; 
• intramuscular/intravenous, 300–




100 mg/kg per day, q12h; 
8–28 days:
• intramuscular/intravenous, 
150 mg/kg per day, q8h; 
 > 2 months:
• intramuscular/intravenous, 
200 mg/kg per day, q6h
• oral/intravenous, 100–400 mg/
kg per day, q6h
Azithromycin 6 months – 17 years:
• oral, 10 mg/kg per day, q24h; 
• oral, 200 mg/day, q24h (weight: 
15–25 kg); 
• oral, 300 mg/day, q24h (weight: 
26–35 kg); 
• oral, 400 mg/day, q24h (weight: 
36–45 kg); 
• oral, 500 mg/day, q24h (weight: 
> 45 kg)
1 month – 12 years:
• oral, 10 mg/kg per day, q24h 
(weight: < 15 kg); 
• oral, 200 mg/day, q24h (weight: 
15–25 kg); 
• oral, 300 mg/day, q24h (weight: 
26–35 kg); 
• oral, 400 mg/day, q24h (weight: 
36–45 kg); 
•oral, 500 mg/day, q24h (weight: 
> 45 kg); 
12–18 years:
• oral, 1000 mg/day, q24h
≤ 28 days:
• intravenous/oral, 10 mg/kg per day, 
q24h; 
> 28 days:
• oral, 5–10 mg/kg per day (immediate-
release formulation), q24h; 
• oral, 60 mg/kg per day (extended-
release formulation), q24h
No information • oral, 10 mg/kg per day, q24h
(continues. . .)
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Antibiotic Guidelines, dosing recommendations, by age group, administration route, dosage, frequency
BNF for childrena Blue bookb Red book® c Pocket bookd Indian National Centre for 
Disease Controle
Aztreonam < 7 days:
• intravenous, 60 mg/kg per day, q12h; 
7 days – 1 month:
• intravenous, 90–120 mg/kg per day, 
q6h–q8h; 
 > 1 month – 11 years:
• intravenous, 90–120 mg/kg per day, 
q6h–q8h; 
12–17 years:
• intravenous, 3000 mg/day, q8h
≤ 7 days:
• intravenous, 60 mg/kg per day, 
q12h; 
7 days – 1 month:
• intravenous, 90–120 mg/kg per 
day, q6h–q8h; 
1 month – 2 years:
• intravenous, 90–120 mg/kg per 
day, q6h–q8h; 
2–18 years:
• intravenous, 90 mg/kg per day, 
q8h; 
• intravenous, 200 mg/kg per day, 
q6h (severe infection)
≤ 7 days:
• intravenous, 30 mg/kg per day, q12h 
(GA: < 34 weeks); 
• intravenous, 30 mg/kg per day, q8h 
(GA: ≥ 34 weeks); 
> 7–28 days:
• intravenous, 30 mg/kg per day, q8h 
(GA: < 34 weeks); 
• intravenous, 30 mg/kg per day, q6h 
(GA: ≥ 34 weeks); 
> 28 days:
• intramuscular/intravenous, 90–
120 mg/kg per day, q6h–q8h





• intramuscular/intravenous, 50 mg/kg 
per day, q12h; 
7–28 days:
• intramuscular/intravenous, 75 mg/kg 
per day, q8h; 
Child:
• intramuscular/intravenous, 100 mg/kg 
per day, q6h
≤ 7 days:
• intravenous, 50 mg/kg per day, 
q12h; 
7–28 days:
• intravenous, 75 mg/kg per day, 
q8h; 
1 month:
• intravenous, 150 mg/kg per day, 
q8h (severe infection); 
• intravenous, 225 mg/kg per day, 
q8h (meningitis); 
1 month – 18 years:
• intravenous, 100 mg/kg per day, 
q6h; 
• intravenous, 200–300 mg/kg per 
day, q4h–q6h (severe infection)
≤ 7 days:
• intravenous/intramuscular, 50 000 IU/
kg per day (penicillin G aqueous), q12h; 
• intramuscular, 50 000 IU/kg per day 
(penicillin G procaine), q24h; 
> 7–28 days:
• intravenous, 150 000 IU/kg per day, 
q8h; 
> 28 days:
• intramuscular/intravenous, 100 000–
300 000 IU/kg per day, q4h–q6h; 
• intramuscular/intravenous, 300 000–
400 000 IU/kg per day, q4h (meningitis)
≤ 7 days:
• 100 000 IU/kg per day, 
q12h; 
8 days – 2 months:




200 000 IU/kg per day, q6h; 
• intramuscular/intravenous, 
400 000 IU/kg per day, q6h 
(meningitis)
• oral, 200 000 IU/kg per day, q6h; 
• intravenous, 200 000–
400 000 IU/kg per day, q6h
Cefalexin < 7 days:
• oral, 50 mg/kg per day, q12h; 
7–20 days:
• oral, 75 mg/kg per day, q8h; 
21–28 days:
• oral, 100 mg/kg per day, q6h; 
1–11 months:
• oral, 25 mg/kg per day, q12h; 
1–4 years:
• oral, 25 mg/kg per day, q12h; 
5–11 years:
• oral, 25 mg/kg per day, q12h; 
12–17 years:
• oral, 1000–1500 mg/day, q8h–q12h
≤ 7 days:
• oral, 50 mg/kg per day, q12h; 
7–21 days:
• oral, 75 mg/kg per day, q8h; 
21–28 days:
• oral, 100 mg/kg per day, q6h; 
1 month – 18 years:
• oral, 25–50 mg/kg per day, q6h
> 28 days:
• oral, 25–50 mg/kg per day, q12h; 
• oral, 75–100 mg/kg per day, q6h–q8h 
(bone or joint infection)
• oral, 50 mg/kg per day, 
q6h
• oral, 30–40 mg/kg per day, q8h
Cefazolin No information No information ≤ 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
 > 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 < 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
 ≥ 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 > 28 days:
• intramuscular/intravenous, 25–
75 mg/kg per day, q8h; 
• intramuscular/intravenous, up to 
150 mg/kg per day, q6h–q8h (bone or 
joint infection)
No information • intravenous, 100 mg/kg per day, 
q6h–q8h
Cefotaxime < 7 days:
• intramuscular/intravenous, 50 mg/kg 
per day, q12h; 
• intramuscular/intravenous, 100 mg/kg 
per day, q12h (meningitis); 
7–20 days:
• intramuscular/intravenous, 75 mg/kg 
per day, q8h; 
• intramuscular/intravenous, 150 mg/kg 
per day, q8h (meningitis); 
21–28 days:
• intramuscular/intravenous, 75–
100 mg/kg per day, q6h–q8h; 
• intramuscular/intravenous, 
150–200 mg/kg per day, q6h–q8h 
(meningitis); 
Child:
• oral, 100–150 mg/kg per day, q8h–
q12h; 
• intramuscular/intravenous, 
200–300 mg/kg per day, q8h–q12h 
(meningitis)
≤ 7 days:
• intravenous, 50–100 mg/kg per 
day, q12h; 
7–21 days:
• intravenous, 75–150 mg/kg per 
day, q8h; 
21–28 days:
• intravenous, 100–200 mg/kg per 
day, q6h; 
1 month – 18 years:
• intravenous, 150–200 mg/kg per 
day, q6h–q8h
≤ 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
> 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
< 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
 ≥ 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 > 28 days:
• intramuscular/intravenous, 150–
180 mg/kg per day, q8h; 
• intramuscular/intravenous, 200–
225 mg/kg per day, q6h (meningitis)
< 7 days:
• intravenous, 150 mg/kg 
per day, q8h; 
2–4 weeks:
• intravenous, 200 mg/kg 
per day, q6h; 
 > 2 months:
• intravenous, 200 mg/kg 
per day, q6h
• intravenous, 100 mg/kg per day, 
q6h–q8h; 
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Ceftazidime < 7 days:
• intravenous, 25 mg/kg per day, q24h; 
7–20 days:
• intravenous, 50 mg/kg per day, q12h; 
21–28 days:
• intravenous, 75 mg/kg per day, q8h; 
Child:
• intravenous, 75 mg/kg per day, q8h
≤ 7 days:
• intravenous, 25–50 mg/kg per day, 
q24h; 
7–21 days:
• intravenous, 50–100 mg/kg per 
day, q12h; 
21–28 days:
• intravenous, 75–150 mg/kg per 
day, q8h; 
1 month – 18 years:
• intravenous, 25–50 mg/kg per day, 
q24h
≤ 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
 > 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 < 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
≥ 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 > 28 days:
• intramuscular/intravenous, 90–
150 mg/kg per day, q8h; 
• intramuscular/intravenous, 
200–300 mg/kg per day, q8h (severe 
Pseudomonas infection)
No information • intramuscular/intravenous, 
75–100 mg/kg per day, q8h; 
• intravenous, 100 mg/kg per day, 
q8h (meningitis)
Ceftriaxone < 15 days:
• intravenous, 20–50 mg/kg per day, 
q24h; 
15–28 days:
• intravenous, 50–80 mg/kg per day, 
q24h; 
1 month – 11 years (weight: < 50 kg):
• intramuscular/intravenous, 50–80 mg/
kg per day, q24h; 
9–11 years (weight: ≥ 50 kg):
• intramuscular/intravenous, 1000–






25–50 mg/kg per day, q24h; 
1 month – 18 years:
• intramuscular/intravenous, 
50–80 mg/kg per day, q24h; 
• intramuscular/intravenous, 80 mg/
kg per day, q24h (meningitis)
> 28 days:
• intramuscular/intravenous, 50–
75 mg/kg per day, q24h; 
• intramuscular/intravenous, 100 mg/
kg per day, q12h–q24h (severe 
infection); 
• intramuscular, 50 mg/kg per day, 
q24h (acute otitis media)
< 2 months:
• intramuscular/intravenous, 
100 mg/kg per day, q12h–
q24h; 
 > 2 months:
• intravenous, 80 mg/kg per 
day, q24h; 
• intramuscular/intravenous, 
100 mg/kg per day, q12h 
(meningitis)
• intravenous, 50–100 mg/kg per 
day, q12h; 
• intravenous, 100 mg/kg per day, 
q12h (meningitis)
Cefuroxime < 7 days:
• intravenous, 50 mg/kg per day, q12h; 
7–20 days:
• intravenous, 75 mg/kg per day, q8h; 
21–28 days:
• intravenous, 100 mg/kg per day, q6h; 
Child:
• intramuscular/intravenous, 60 mg/kg 
per day, q8h; 
3 months – 1 year:
• oral, 20 mg/kg per day, q12h; 
2–11 years:
• oral, 30 mg/kg per day, q12h; 
12–17 years:
• oral, 500 mg/day, q12h
≤ 7 days:
• intravenous, 50–100 mg/kg per 
day, q12h; 
7–21 days:
• intravenous, 75–150 mg/kg per 
day, q8h; 
21–28 days:
• intravenous, 100–200 mg/kg per 
day, q6h; 
1 month – 18 years:
• intravenous, 60–240 mg/kg per 
day, q6h–q8h; 
3 months – 18 years:
• oral, 20–30 mg/kg per day, q12h
≤ 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
 > 7 days (GA: ≥ 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 < 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q12h; 
 ≥ 14 days (GA: < 32 weeks):
• intravenous/intramuscular, 50 mg/kg 
per day, q8h; 
 > 28 days:
• oral, 20–30 mg/kg per day 
(cefuroxime axetil), q12h; 
• oral, ≤ 100 mg/kg per day (cefuroxime 
axetil), q8h (bone or joint infection); 
• intravenous/intramuscular, 100–
150 mg/kg per day, q8h
No information • oral, 20–30 mg/kg per day, 
q12h; 
• intravenous, 75–100 mg/kg per 
day, q8h
Chloramphenicol < 14 days:
• intravenous, 25 mg/kg per day, q12h; 
14–28 days:
• intravenous, 25–50 mg/kg per day, 
q6h–q12h; 
Child:
• oral/intravenous, 50 mg/kg per day, 
q6h; 
• oral/intravenous, 50 mg/kg per day, 
q6h (meningitis)
≤ 14 days:
• intravenous, 25 mg/kg per day, 
q12h; 
14–28 days:
• intravenous, 37.5–50 mg/kg per 
day, q6h–q8h; 
1 month – 18 years:
• intravenous, 50–100 mg/kg per 
day, q6h
> 28 days:
• intravenous, 50–100 mg/kg per day, 
q6h
• oral, 75 mg/kg per day, 
q8h; 
• intravenous, 100 mg/kg 
per day, q6h (meningitis)
> 3 months:
• oral/intravenous, 75–100 mg/kg 
per day, q6h
Ciprofloxacin Neonate:
• oral, 30 mg/kg per day, q12h; 
• intravenous, 20 mg/kg per day, q12h; 
Child:
• oral, 40 mg/kg per day, q12h; 
• intravenous, 30 mg/kg per day, q8h
< 28 days:
• oral, 20–30 mg/kg per day, q12h; 
• intravenous, 12–20 mg/kg per day, 
q12h; 
1 month – 18 years:
• oral, 30 mg/kg per day, q12h; 
• intravenous, 20–30 mg/kg per day, 
q8h–q12h
> 28 days:
• oral, 20–40 mg/kg per day, q12h; 
• intravenous, 20–30 mg/kg per day, 
q8h–q12h
• oral, 20–40 mg/kg per day, 
q12h
• oral/intravenous, 20–30 mg/kg 
per day, q12h
Clarithromycin Neonate:
• oral, 15 mg/kg per day, q12h; 
1 month – 11 years:
• oral, 15 mg/kg per day, q12h (weight: 
< 8 kg); 
• oral, 125 mg/day, q12h (weight: 
8–11 kg); 
• oral, 250 mg/day, q12h (weight: 
12–19 kg); 
• oral, 375 mg/day, q12h (weight: 
20–29 kg); 
• oral, 500 mg/day, q12h (weight: 
30–40 kg); 
• intravenous, 15 mg/kg per day, q12h; 
12–17 years:
• oral, 500 mg/day, q12h; 
• intravenous, 1000 mg/day, q12h
< 28 days:
• oral, 15 mg/kg per day, q12h; 
• intravenous, 15 mg/kg per day, 
q12h; 
1 month – 18 years:
• oral, 15–30 mg/kg per day, q12h; 
• intravenous, 15 mg/kg per day, 
q12h
> 28 days:
• oral, 15 mg/kg per day, q12h
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Clindamycin < 14 days:
• oral, 9–18 mg/kg per day, q8h; 
14 days – 1 month:
• oral, 12–24 mg/kg per day, q6h; 
1 month – 17 years:
• oral, 12–24 mg/kg per day, q6h; 
• intramuscular/intravenous, 15–25 mg/
kg per day, q6h
< 14 days:
• oral, 9–18 mg/kg per day, q8h; 
14 days – 1 month:
• oral, 12–24 mg/kg per day, q6h; 
1 month – 18 years:
• oral, 24 mg/kg per day, q6h; 
• intravenous, 24–40 mg/kg per day, 
q6h
PMA: ≤ 32 weeks:
• intravenous/oral, 5 mg/kg per day, 
q8h; 
PMA: 33–40 weeks:
• intravenous/oral, 7 mg/kg per day, 
q8h; 
PMA: > 40 weeks:
• intravenous/oral, 9 mg/kg per day, 
q8h; 
 > 28 days:
• oral, 10–25 mg/kg per day, q8h; 
• oral, 30–40 mg/kg per day, q6h–q8h 




40 mg/kg per day, q6h–q8h





• oral/intravenous, 50 mg/kg per day, 
q12h; 
7–20 days:
• oral/intravenous, 75 mg/kg per day, 
q8h; 
21–28 days:
• oral/intravenous, 100 mg/kg per day, 
q6h; 
1 month – 1 year:
• oral, 250–500 mg/day, q6h; 
2–9 years:
• oral, 500–1000 mg/day, q6h; 
10–17 years:
• oral, 1000–2000 mg/day, q6h; 
Child:
• intramuscular/intravenous, 50–
100 mg/kg per day, q6h
< 7 days:
• oral/intravenous, 50 mg/kg per 
day, q12h; 
• intravenous, 100 mg/kg per day, 
q12h (severe infection); 
7–21 days:
• oral/intravenous, 75 mg/kg per 
day, q8h; 
• intravenous, 150 mg/kg per day, 
q8h (severe infection); 
> 21–28 days:
• oral, 100 mg/kg per day, q6h; 
• intravenous, 200 mg/kg per day, 
q6h (severe infection); 
1 month – 18 years:
• oral, 100 mg/kg per day, q6h; 
• intravenous, 100–200 mg/kg per 
day, q6h
No information < 7 days:
• intravenous, 50–100 mg/
kg per day, q12h; 
2–4 weeks:
• intravenous, 75–150 mg/
kg per day, q8h; 
> 2 months:
• intramuscular/intravenous, 
100–200 mg/kg per day, 
q6h
• oral, 50–100 mg/kg per day, 
q6h–q8h; 
• intravenous, 100–200 mg/kg 
per day, q6h
Doxycycline 12–17 years:
• oral, 100 mg/day, q24h
12–18 years:
• oral, 200 mg/day, q12h
> 28 days:
• oral/intravenous, 2.2–4.4 mg/kg per 
day, q12h
No information No information
Erythromycin < 1 month:
• oral, 50 mg/kg per day, q6h; 
• intravenous, 40–50 mg/kg per day, 
q6h; 
1 month – 1 year:
• oral, 500 mg/day, q6h–q12h; 
2–7 years:
• oral, 1000 mg/day, q6h–q12h; 
8–17 years:
• oral, 1000–2000 mg/day, q6h–q12h; 
Child:
• intravenous, 50 mg/kg per day, q6h
< 28 days:
• oral, 50 mg/kg per day, q6h; 
• intravenous, 40–50 mg/kg per day, 
q6h; 
1 month – 18 years:
• oral, 50–100 mg/kg per day, q6h; 
• intravenous, 50 mg/kg per day, q6h
≤ 28 days:
• intravenous/oral, 10 mg/kg per day, 
q6h; 
> 28 days:
• oral, 40–50 mg/kg per day, q6h–q8h; 
• intravenous, 20 mg/kg per day, q6h
• oral, 50 mg/kg per day, 
q6h
• oral, 40 mg/kg per day, q6h
Gentamicin 1 month – 11 years:
• intramuscular/intravenous, 7.5 mg/kg 
per day, q8h; 
Child:
• intravenous, 7 mg/kg per day, q24h; 
12–17 years:
• intramuscular/intravenous, 6 mg/kg 
per day, q8h
Neonate:
• intravenous, 5 mg/kg per dose, 
q36h (CGA: < 32 weeks); 
• intravenous, 5 mg/kg per day, q24h 
(CGA: > 32 weeks); 
1 month – 18 years:
• intravenous, 7 mg/kg per day, q24h
≤ 7 days (GA: ≥ 35 weeks):
• intramuscular/intravenous, 4 mg/kg 
per day, q24h; 
> 7 days (GA: ≥ 35 weeks):
• intramuscular/intravenous, 5 mg/kg 
per day, q24h; 
≤ 14 days:
• intramuscular/intravenous, 5 mg/kg 
per day, q48h (GA: < 30 weeks); 
• intramuscular/intravenous, 5 mg/kg 
per day, q36h (GA: 30–34 weeks); 
 > 14 days:
• intramuscular/intravenous, 5 mg/kg 
per day, q36h (GA: < 30 weeks); 
• intramuscular/intravenous, 5 mg/kg 
per day, q24h (GA: 30–34 weeks); 
 > 28 days:
• intramuscular/intravenous, 6–7.5 mg/
kg per day, q8h; 
• intramuscular/intravenous, 5–7.5 mg/
kg per day, q24h
7 days:
• intramuscular/intravenous, 
5 mg/kg per day, q24h; 
2–4 weeks:
• intramuscular/intravenous, 
7.5 mg/kg per day, q24h; 
 > 2 months:
• intramuscular/intravenous, 
7.5 mg/kg per day, q24h
• intramuscular/intravenous, 




• intravenous, 40 mg/kg per day, q12h; 
7–20 days:
• intravenous, 60 mg/kg per day, q8h; 
21–28 days:
• intravenous, 80 mg/kg per day, q6h; 
1–2 months:
• intravenous, 80 mg/kg per day, q6h; 
3 months – 17 years:
• intravenous, 60 mg/kg per day, q6h
≤ 7 days:
• intravenous, 30 mg/kg per day, 
q12h; 
7–21 days:
• intravenous, 45 mg/kg per day, 
q8h; 
21–28 days:
• intravenous, 60 mg/kg per day, 
q6h; 
1–3 months:
• intravenous, 60 mg/kg per day, 
q8h; 
3 months – 18 years:
• intravenous, 60 mg/kg per day, q6h
≤ 28 days:
• intravenous, 25 mg/kg per day, q12h 
(PNA: ≤ 7 days); 
• intravenous, 25 mg/kg per day, q8h 
(PNA: > 7 days); 
> 28 days:
• intravenous, 60–100 mg/kg per day, 
q6h
No information < 3 months:
• oral/intravenous, 100 mg/kg per 
day, q6h; 
> 3 months:
• oral/intravenous, 60–100 mg/kg 
per day, q6h
Levofloxacin No information No information ≥ 6 months:
• intravenous/oral, 16 mg/kg per day, 
q12h (weight: < 50 kg); 
• intravenous/oral, 500 mg/day, q24h 
(weight: > 50 kg)
No information 6 months – 5 years:
• NRS, 20 mg/kg per day, q12h; 
> 5 years:
• NRS, 10 mg/kg per day, q24h
(. . .continued)
(continues. . .)
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Linezolid < 7 days:
• oral/intravenous, 20 mg/kg per day, 
q12h; 
7–28 days:
• oral/intravenous, 30 mg/kg per day, 
q8h; 
1 month – 11 years:
• oral/intravenous, 30 mg/kg per day, 
q8h; 
12–17 years:
• oral/intravenous, 1200 mg/day, q12h
≤ 7 days:
• oral/intravenous, 20 mg/kg per 
day, q12h; 
 > 7–28 days:
• oral/intravenous, 30 mg/kg per 
day, q8h; 
1 month – 12 years:
• oral/intravenous, 30 mg/kg per 
day, q8h; 
 > 12–18 years:
• oral/intravenous, 1200 mg/day, 
q12h
≤ 7 days:
• intravenous/oral, 10 mg/kg per day, 
q12h (GA: < 34 weeks); 
• intravenous/oral, 10 mg/kg per day, 
q8h (GA: ≥ 34 weeks); 
 > 7 days:
• intravenous/oral, 10 mg/kg per day, 
q8h (GA: < 34 weeks); 
• intravenous/oral, 10 mg/kg per day, 
q8h (GA: ≥ 34 weeks); 
28 days – 11 years:
• oral/intravenous, 30 mg/kg per day, 
q8h; 
> 11 years:
• oral/intravenous, 1200 mg/day, q12h
No information • oral/intravenous, 30–40 mg/kg 
per day, q6h–q8h
Meropenem < 7 days:
• intravenous, 40 mg/kg per day, q12h; 
7–28 days:
• intravenous, 60 mg/kg per day, q8h; 
1 month – 11 years:
• intravenous, 30–60 mg/kg per day, q8h 
(weight: < 50 kg); 
• intravenous, 1500–3000 mg/day, q8h 
(weight: ≥ 50kg); 
12–17 years:
• intravenous, 1500–3000 mg/day, q8h
≤ 7 days:
• intravenous, 80 mg/kg per day, 
q12h; 
> 7–28 days:
• intravenous, 120 mg/kg per day, 
q8h; 
1 month – 12 years:
• intravenous, 30–120 mg/kg per 
day, q8h
< 14 days:
• intravenous, 20 mg/kg per day, q12h 
(GA: < 32 weeks); 
• intravenous, 20 mg/kg per day, q8h 
(GA: ≥ 32 weeks); 
≥ 14 days:
• intravenous, 20 mg/kg per day, q8h 
(GA: < 32 weeks); 
• intravenous, 30 mg/kg per day, q8h 
(GA: ≥ 32 weeks); 
> 28 days:
• intravenous, 60 mg/kg per day, q8h; 
• intravenous, 120 mg/kg per day, q8h 
(meningitis)
No information > 3 months:
• intravenous, 60 mg/kg per day, 
q8h
Metronidazole Neonate:
• intravenous, 7.5 mg/kg per day, q24h 
(CGA: < 26 weeks); 
• intravenous, 15 mg/kg per day, q12h 
(CGA: 26–34 weeks); 
• intravenous, 22.5 mg/kg per day, q8h 
(CGA: ≥ 34 weeks); 
1 month:
• oral, 15 mg/kg per day, q12h; 
• intravenous, 22.5 mg/kg per day, q8h; 
 > 1–11 month:
• rectal, 375 mg/day, q8h; 
2 months – 11 years:
• oral, 22.5 mg/kg per day, q8h; 
2 months – 17 years:
• intravenous, 22.5 mg/kg per day, q8h; 
1–4 years:
• rectal, 750 mg/day, q8h; 
5–9 years:
• rectal, 1500 mg/day, q8h; 
10–17 years:
• rectal, 3000 mg/day, q8h; 
12–17 years:
• oral, 1200 mg/day, q8h
< 28 days:
• oral/intravenous, 15 mg/kg per 
day, q12h; 
1 month – 18 years:
• oral/intravenous, 22.5 mg/kg per 
day, q8h
≤ 28 days:
• intravenous, 7.5 mg/kg per day, q12h 
(PMA: ≤ 34 weeks); 
• intravenous, 7.5 mg/kg per day, q8h 
(PMA: 35–40 weeks); 
• intravenous, 10 mg/kg per day, q8h 
(PMA: > 40 weeks); 
 > 28 days:
• oral, 15–50 mg/kg per day, q8h; 
• intravenous, 22.5–40 mg/kg per day, 
q6h–q8h
• oral, 22.5 mg/kg per day, 
q8h
• oral/intravenous, 22.5 mg/kg 
per day, q8h
Nitrofurantoin 3 months – 11 years:
• oral, 3 mg/kg per day, q6h; 
12–17 years:
• oral, 200 mg/day, q6h (q12h with 
modified-release formulation)
3 months – 18 years:
• oral, 4 mg/kg per day, q6h
> 28 days:
• oral, 5–7 mg/kg per day, q6h




• oral, 250 mg/day, q6h; 
1–5 years:
• oral, 500 mg/day, q6h; 
6–11 years:
• oral, 1000 mg/day, q6h; 
12–17 years:
• oral, 2000 mg/day, q6h
1 month – 18 years:
• oral, 60 mg/kg per day, q6h
> 28 days:
• oral, 25–50 mg/kg per day, q6h
No information • oral, 20–50 mg/kg per day, q6h
Piperacillin–tazobactam < 1 month:
• intravenous, 270 mg/kg per day, q8h; 
1 month – 11 years:
• intravenous, 270–360 mg/kg per day, 
q6h–q8h; 
12–17 years:
• intravenous, 13 500 mg/day, q8h
< 28 days:
• intravenous, 270 mg/kg per day, 
q8h; 
1 month – 18 years:
• intravenous, 270–360 mg/kg per 
day, q6h–q8h
≤ 28 days:
• intravenous, 100 mg/kg per day, q8h 
(PMA: ≤ 30 weeks); 
• intravenous, 80 mg/kg per day, q6h 
(PMA: > 30 weeks); 
 > 28 days:
• intravenous, 240–300 mg/kg per day, 
q6h–q8h
No information • intravenous, 200–400 mg/kg 
per day, q6h–q8h
Trimethoprim < 1 month:
• oral, 2–4 mg/kg per day, q12h; 
4 weeks – 11 years
• oral, 8 mg/kg per day, q12h; 
12–17 years:
• oral, 400 mg/day, q12h
< 28 days:
• oral, 2–4 mg/kg per day, q12h; 
1 month – 18 years:
• oral, 8 mg/kg per day, q12h
No information No information No information
Trimethoprim–
sulfamethoxazole
6 weeks – 5 months:
• oral, 240 mg/day, q12h; 
6 weeks – 17 years:
• intravenous, 36 mg/kg per day, q12h; 
• intravenous, 54 mg/kg per day, q12h 
(severe infection); 
6 months – 5 years:
• oral, 480 mg/day, q12h; 
6 years – 11 years:
• oral, 960 mg/day, q12h; 
12–17 years:
• oral, 1920 mg/day, q12h
6 weeks – 18 years:
• oral, 48 mg/kg per day, q12h
> 28 days:
• oral/intravenous, 8–10 mg/kg per 
day, q12h
≤ 1 month:
• oral, 4 mg/kg per day 
of trimethoprim and 
20 mg/kg per day of 
sulfamethoxazole, q12h; 
 > 2 months:
• oral, 8 mg/kg per day 
of trimethoprim and 
40 mg/kg per day of 
sulfamethoxazole, q12h
• oral, 5–10 mg/kg per day, q12h
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Paediatric dosing guidelines for antibiotics Shrey Mathur et al.
Antibiotic Guidelines, dosing recommendations, by age group, administration route, dosage, frequency
BNF for childrena Blue bookb Red book® c Pocket bookd Indian National Centre for 
Disease Controle
Vancomycin Neonate:
• intravenous, 15 mg/kg per day, q24h 
(CGA: < 29 weeks); 
• intravenous, 30 mg/kg per day, q12h 
(CGA: 29–35 weeks); 
• intravenous, 45 mg/kg per day, q8h 
(CGA: > 35 weeks); 
Child:
• intravenous, 45 mg/kg per day, q8h
Neonate:
• intravenous, 15 mg/kg per day, 
q24h (PMA: < 29 weeks); 
• intravenous, 30 mg/kg per day, 
q12h (PMA: 29–35 weeks); 
• intravenous, 45 mg/kg per day, q8h 
(PMA: > 35 weeks); 
1 month – 18 years:
• intravenous, 45 mg/kg per day, q8h
< 28 days (GA: ≤ 28 weeks):
• NRS, 15 mg/kg per day, q12h (CrS: 
< 0.5 mg/dL); 
• NRS, 20 mg/kg per day, q24h (CrS: 
0.5–0.7 mg/dL); 
• NRS, 15 mg/kg per day, q24h (CrS: 
0.8–1 mg/dL); 
• NRS, 10 mg/kg per day, q24h (CrS: 
1.1–1.4 mg/dL); 
• NRS, 15 mg/kg per day, q48h (CrS: 
> 1.4 mg/dL); 
< 28 days (GA: > 28 weeks):
• NRS, 15 mg/kg per day, q12h (CrS: 
< 0.7mg/dL); 
• NRS, 20 mg/kg per day, q24h (CrS: 
0.7–0.9 mg/dL); 
• NRS, 15 mg/kg per day, q24h (CrS: 
1–1.2 mg/dL); 
• NRS, 10 mg/kg per day, q24h (CrS: 
1.3–1.6 mg/dL); 
• NRS, 15 mg/kg per day, q48h (CrS: 
> 1.6 mg/dL); 
> 28 days:
• intravenous, 45–60 mg/kg per day, 
q6h–q8h; 
• oral, 40 mg/kg per day, q6h
No information • intravenous, 40–60 mg/kg per 
day, q6h–q8h
CGA: corrected gestational age; CrS: serum creatinine; GA: gestational age; IU: international unit; NRS: no route of administration specified; PMA: postmenstrual age; PNA: postnatal age; q6h: every 6 hours; q8h: every 8 hours; q12h: every 12 hours; q24h: 
every 24 hours; q36h: every 36 hours; q48h: every 48 hours.
a  BNF (British national formulary) for children.25
b  Manual of childhood infections: the blue book, 4th edition.11
c  Red book®: 2018–2021 report of the committee on infectious diseases, 31st edition.26
d  Pocket book of hospital care for children, second edition.27
e  National treatment guidelines for antimicrobial use in infectious diseases.28
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